These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25600037)

  • 41. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus.
    Al Jobori H; Daniele G; Adams J; Cersosimo E; Solis-Herrera C; Triplitt C; DeFronzo RA; Abdul-Ghani M
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1402-1407. PubMed ID: 29342295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
    Ferrannini G; Hach T; Crowe S; Sanghvi A; Hall KD; Ferrannini E
    Diabetes Care; 2015 Sep; 38(9):1730-5. PubMed ID: 26180105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
    Famulla S; Pieber TR; Eilbracht J; Neubacher D; Soleymanlou N; Woerle HJ; Broedl UC; Kaspers S
    Diabetes Technol Ther; 2017 Jan; 19(1):49-60. PubMed ID: 27929674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms linking empagliflozin to cardiovascular and renal protection.
    Perrone-Filardi P; Avogaro A; Bonora E; Colivicchi F; Fioretto P; Maggioni AP; Sesti G; Ferrannini E
    Int J Cardiol; 2017 Aug; 241():450-456. PubMed ID: 28395981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2014 Oct; 74(15):1769-84. PubMed ID: 25274537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
    Ferrannini E; Muscelli E; Frascerra S; Baldi S; Mari A; Heise T; Broedl UC; Woerle HJ
    J Clin Invest; 2014 Feb; 124(2):499-508. PubMed ID: 24463454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus.
    Chawla G; Chaudhary KK
    Diabetes Metab Syndr; 2019; 13(3):2001-2008. PubMed ID: 31235127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE
    Han JH; Oh TJ; Lee G; Maeng HJ; Lee DH; Kim KM; Choi SH; Jang HC; Lee HS; Park KS; Kim YB; Lim S
    Diabetologia; 2017 Feb; 60(2):364-376. PubMed ID: 27866224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.
    Hansen HH; Jelsing J; Hansen CF; Hansen G; Vrang N; Mark M; Klein T; Mayoux E
    J Pharmacol Exp Ther; 2014 Sep; 350(3):657-64. PubMed ID: 24993361
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus.
    Heise T; Jordan J; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
    Clin Ther; 2016 Oct; 38(10):2248-2264.e5. PubMed ID: 27666126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia.
    Goh KG; Zakaria MH; Raja Azwan RN; Bhajan Singh KK; Badrul Hisham MH; Hussein Z
    Diabetes Metab Syndr; 2023 Jan; 17(1):102680. PubMed ID: 36473336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study.
    Kaku K; Nakayama Y; Yabuuchi J; Naito Y; Kanasaki K
    Expert Opin Drug Saf; 2023; 22(9):819-832. PubMed ID: 37194266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice.
    Lu YH; Chang YP; Li T; Han F; Li CJ; Li XY; Xue M; Cheng Y; Meng ZY; Han Z; Sun B; Chen LM
    Int J Biol Sci; 2020; 16(3):529-542. PubMed ID: 32015688
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats.
    Korkmaz Y; Dik B
    Fundam Clin Pharmacol; 2024 Jun; 38(3):511-522. PubMed ID: 38149676
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Empagliflozin-Mediated Lithium Excretion: A Case Study and Clinical Applications.
    Armstrong GP
    Am J Case Rep; 2020 Jun; 21():e923311. PubMed ID: 32518219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful use of empagliflozin in medically refractory post-bariatric surgery hypoglycaemia.
    Park YA; Chhabra M; Sim IW
    Intern Med J; 2024 May; 54(5):836-837. PubMed ID: 38757202
    [No Abstract]   [Full Text] [Related]  

  • 58. Empagliflozin Protects against Pulmonary Ischemia/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism.
    Huang D; Ju F; Du L; Liu T; Zuo Y; Abbott GW; Hu Z
    J Pharmacol Exp Ther; 2022 Mar; 380(3):230-241. PubMed ID: 34893552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SGLT2 Inhibition with Empagliflozin as a Possible Therapeutic Option for Postprandial Hypoglycemia After Bariatric Surgery.
    Carpentieri GB; Gonçalves SEAB; Casagrande MZ; Mourad WM; Pinto LGC; Zanella MT
    Obes Surg; 2022 Aug; 32(8):2664-2671. PubMed ID: 35674979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: A short-term observational study.
    Chacko J; Dhandapani S; Jahagiridhar V; Swaminathan K
    Indian J Pharmacol; 2021; 53(3):229-233. PubMed ID: 34169909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.